Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in Extensive-Stage Small Cell Lung Cancer
Cancers · 15.05.2026 · 18 (10) · 1608
DOI: 10.3390/cancers18101608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 15.05.2026. Verfasst von Shengjuan Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
Small cell lung cancer (SCLC) carries a dismal prognosis with limited biomarkers for risk stratification. This study aimed to identify circulating prognostic biomarkers.
Methods
We prioritized SCLC risk-associated genes using Summary-data-based Mendelian Randomization of pQTL/eQTL, differential expression, and weighted gene co-expression network analysis. Five machine learning approaches were compared to develop a diagnostic model based on ACE, AGER, and IL18R1, trained on GSE149507 and validated in GSE60052. We conducted single-cell transcriptomic analysis using public datasets (GSE150766 and GSE279570) and peripheral blood mononuclear cells (PBMCs) from our extensive-stage cohort. Finally, prioritizing the lead candidate IL18R1, we enrolled a prospective clinical cohort to assess its prognostic utility. A LASSO–Cox prognostic model incorporating plasma IL18R1 and clinical variables was internally validated (7:3 split) for progression-free survival (PFS) prediction.
Results
Integrative multi-omics identified ACE, AGER, and IL18R1 as SCLC-protective genes. Elastic Net machine learning identified a two-gene predictive signature (AGER and IL18R1) with robust diagnostic accuracy. Single-cell RNA sequencing revealed the predominant downregulation of ACE, AGER, and IL18R1 in T cells and alveolar type II cells from SCLC patients. PBMC analysis further supported IL18R1 downregulation in CD8+ T cells, NK cells, and dendritic cells. In an independent prospective cohort (n = 300), lower plasma IL18R1 levels were independently associated with shorter PFS (HR = 0.997 per unit increase; 95% CI: 0.995–0.999; and p = 0.003), with time-dependent AUCs of 0.77–0.86. Performance in limited-stage disease was inconsistent and requires further validation. A prognostic model incorporating plasma IL18R1 and 11 clinical parameters stratified patients into distinct risk groups (HR = 5.19), showing a strong discriminative ability in extensive-stage SCLC.
Conclusions
We identified ACE, AGER, and IL18R1 as protective factors against SCLC progression. Integration of plasma IL18R1 with clinical parameters provides a prognostic tool for extensive-stage SCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
- Traditional Chinese Medicine Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Department of Oncology, The Mongolia-Chinese Medical Hospital of Chifeng, Chifeng 024000, China.
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 511436, China.
- Beijing Key Laboratory of Digital Intelligence Traditional Chinese Medicine Oncology Prevention and Treatment, Beijing 100021, China.
ORCID-Profile: Shengjuan Hu, Sicong Li
Förderung
- the National Key Research and Development Program of China
- National Key Research and Development Program of China
Zitieren
APA
Hu, S., Li, S., Cui, Y., Wang, Y., Chen, L., Zhang, X., Hou, L., & Feng, L. (2026). Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in Extensive-Stage Small Cell Lung Cancer. Cancers, 18(10), 1608. https://doi.org/10.3390/cancers18101608
Vancouver
Hu S, Li S, Cui Y, Wang Y, Chen L, Zhang X, et al. Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in Extensive-Stage Small Cell Lung Cancer. Cancers. 2026;18(10):1608. doi:10.3390/cancers18101608
BibTeX
@article{Hu2026,
author = {Hu, Shengjuan and Li, Sicong and Cui, Yiyuan and Wang, Ying and Chen, Luyao and Zhang, Xiyuan and Hou, Li and Feng, Li},
title = {Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in Extensive-Stage Small Cell Lung Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {10},
pages = {1608},
doi = {10.3390/cancers18101608}
}
EUVIMED